Continuing Education Activity
Acyclovir is a medication used to manage and treat infections caused by the herpes simplex virus (HSV). It is FDA approved to treat genital herpes and HSV encephalitis. Some off-label uses include cold sores, shingles, and chickenpox. It is in the antiviral class of medications. This activity outlines the indications, action, pharmacology, and contraindications for acyclovir as a valuable agent in treating HSV and varicella-zoster-caused diseases.
- Summarize acyclovir's mechanism of action.
- Explain the adverse effects of acyclovir.
- Review the correct administration and necessary monitoring of acyclovir when giving it to a patient.
- Describe the fundamental interprofessional approach when administering acyclovir as part of an interprofessional team administering patient care.
Acyclovir is an agent used to treat infections caused by the herpes simplex virus (HSV). It is FDA approved to treat genital herpes and HSV encephalitis. Non-FDA-approved indications are mucocutaneous HSV, herpes zoster (shingles), and varicella-zoster (chickenpox). Acyclovir is the first-line treatment for HSV encephalitis. Currently, no other medications are indicated for treating this condition.
Despite the long-term use of acyclovir to treat HSV encephalitis, there has not been a systematic review regarding the efficacy of this disease/treatment combination. Current systematic reviews to address its safety and efficacy are currently ongoing, with the primary outcome being the mortality rate. A secondary outcome measure is the quality of life.
HSV keratitis has been shown to respond to oral acyclovir and topical steroids in pediatric patients.
Stromal keratitis with ulceration caused by the herpes simplex virus can be a clinically difficult corneal infection to treat. Pisitpayat, P. et al. examined the efficacy of intravenous acyclovir treatment in two patients. The diagnosis was confirmed by corneal scraping samples, which underwent polymerase chain reaction (PCR) analysis. One patient had herpes simplex virus-1, and the other had herpes simplex virus-2. The patient with herpes simplex virus-1 corneal infection initially received treatment with oral acyclovir. However, the corneal infection worsened and was switched to intravenous acyclovir. The corneal infection gradually improved. The patient with herpes simplex virus-2 corneal infection received treatment with intravenous acyclovir. The corneal infection improved. However, the patient had an epithelial lesion that required additional treatment with 100% autologous serum until the lesion healed. Both patients received prophylactic treatment with oral acyclovir to prevent corneal reinfection
In patients with human immunodeficiency virus (HIV), acyclovir is sometimes used to treat eczema herpeticum. It is also used to prevent infections of the skin, eyes, nose, and mouth. Eczema herpeticum is rare but rapidly progressive if untreated. Those with extensive involvement, systemic symptoms, or decreased oral intake should undergo admission for intravenous acyclovir treatment. Also, acyclovir treats oral hairy leukoplakia.
Acyclovir has been proven useful in treating myelopathy secondary to varicella-zoster infection. In a small case series, researching patients from 1994 to 2014 with laboratory-confirmed varicella-zoster virus (VZV) and MRI-confirmed myelopathy, marked improvement of symptoms was the outcome in most patients within two months.
Brachial plexus neuritis secondary to VZV infection and visceral disseminated VZV infection (characteristic features are abdominal and absence of skin lesions) has also responded to acyclovir, alleviating all symptoms.
In recipients of hematopoietic stem cell transplantation, herpes simplex virus and varicella-zoster reactivation may respond to treatment with acyclovir prophylaxis. Prophylactic use of acyclovir should also be considered in HSV-1 and HSV-2-seropositive organ recipients. Diseases from such viruses have decreased secondary to this intervention. However, a breakthrough infection may occur. Not surprisingly, HSV and VZV infection is not uncommon in patients that have discontinued acyclovir prophylaxis.
Another form of prophylactic acyclovir use is juvenile-onset recurrent respiratory papillomatosis. In a prospective observational study involving 21 patients, oral acyclovir was a postoperative adjuvant. It was shown to decrease the recurrence of papillomas and thus decrease the need for successive surgeries and associated operative risks.
VZV infections have many complications, including cerebellitis. Treating the source infection has been shown to decrease the complication burden as well. A 2019 case report, for instance, describes a patient presenting with truncal ataxia. After intravenous acyclovir treatment, the patient was free of neurologic disability and cerebellitis.  Similarly, paresis secondary to dermatomal herpes zoster infections has been shown to respond to oral acyclovir; this is a rare complication of herpes zoster when the virus affects motor nerve fibers in addition to/instead of the dorsal root ganglion.
Mechanism of Action
Acyclovir is an antiviral agent that incorporates itself into viral DNA preventing further synthesis. It inhibits DNA synthesis and viral replication after its conversion to acyclovir triphosphate by viral and cellular enzymes. Acyclovir is a synthetic purine nucleoside analog that demonstrates in vitro and in vivo inhibitory activity against both herpes simplex virus types 1 (HSV-1), 2 (HSV-2), and varicella-zoster virus.
Acyclovir administration may be oral or intravenous.
For limited mucocutaneous lesions, acyclovir administration can be via the oral route. In cases in which there is disseminated, visceral, or CNS involvement, the acyclovir administration should be intravenous.
When taken orally, acyclovir may be taken with or without food 2 to 5 times a day for 5 to 10 days as well as up to 12 months to prevent outbreaks of genital herpes.
Intravenous administration should be done via IV infusion only, over 1 hour, at a constant rate to prevent renal damage. Medication should be in a diluted D5W solution or 0.9% NaCl to a final concentration of less than or equal to 7 mg/mL.
The following is a non-exhaustive list of dosing regimens:
- HSV Encephalitis - 10 mg/kg IV every 8 hours for 21 days; use ideal body weight for obese patients
- Genital HSV (immunocompetent patients):
- Mild or moderate infection, initial episode - 400 mg orally three times daily for 7 to 10 days
- Severe infection, first episode - 5 to 10 mg/kg IV every 8 hours for 10 days; use ideal body weight for obese patients
- Recurring infection - 400 mg orally three times a day for 5 days. May also use 800 mg orally twice daily for 5 days
- Genital HSV (immunocompromised patients):
- Initial episode - 400 mg orally three times daily for 5 to 10 days
- Recurring infection - 400 mg orally three times a day for 5 days. May also use 800 mg orally twice daily for 5 days
- Varicella-zoster - Chickenpox
- Immunocompetent patients - 800 mg orally four to five times a day for 5 to 7 days
- Immunocompromised patients - 800 mg orally 5 days daily for 7 days
- Varicella-zoster - Shingles
- Immunocompetent patients - 800 mg orally five times a day for 7 days
- Immunocompromised patients - 10 mg/kg IV every 8 hours for 7 days; use ideal body weight for obese patients
Most commonly, patients experience malaise.
Less commonly, patients experience inflammation or phlebitis at the infusion site, nausea, vomiting, transaminitis, and rash (including Steven-Johnson syndrome) when taken intravenously. Rotating infusion sites and decreasing the final infusion concentration to less than 10 mg/mL can help prevent inflammation/phlebitis at the infusion site. Patients also may experience nausea, vomiting, diarrhea, and headache when taken orally.
Least commonly, patients experience abdominal pain, aggression/confusion, agitation, alopecia, anaphylaxis, anemia, angioedema, anorexia, ataxia, coma, disseminated intravascular coagulation (DIC), dizziness, and fatigue.
In certain pediatric patients, acyclovir has been shown to decrease hemoglobin concentrations and the absolute neutrophil count.
The only absolute contraindication to acyclovir is hypersensitivity.
Cautions include renal failure/impairment, immunocompromised host, potential risk of thrombotic thrombocytopenic purpura (TTP), and hemolytic uremic syndrome (HUS)).
Regarding pregnancy and lactation, acyclovir has been shown to cross the placenta. Acyclovir's manufacturer recommends caution during pregnancy and only using it when necessary and indicated, as there have only been a few studies conducted. Specifically, cases of HSV hepatitis have received treatment during pregnancy. Although rare, this condition can become disseminated and fatal in pregnant patients. Although all 56 patients studied had transaminitis, only 18.2% had a vesicular rash. For patients treated with acyclovir empirically, it conferred no risks to the fetus. Acyclovir has been shown to enter breast milk but is generally considered compatible with breastfeeding.
Patients should be monitored for adverse effects such as malaise, inflammation or phlebitis at the infusion site, nausea, vomiting, rash (including Steven-Johnson syndrome), transaminitis, nausea, vomiting, diarrhea, headache, abdominal pain, aggression/confusion, agitation, alopecia, anaphylaxis, anemia, angioedema, anorexia, ataxia, coma, disseminated intravascular coagulation (DIC), dizziness and fatigue.
Acute kidney injury (AKI) is the most significant side effect of parenteral acyclovir administration. The incidence of AKI is comparable to other nephrotoxic medications such as aminoglycosides. Patients with CKD are at higher risk. Dose adjustment of acyclovir for ideal body weight and baseline renal function is imperative. A study regarding the pharmacokinetics of acyclovir demonstrated that a patient's glomerular filtration and tubular secretion contribute to its renal excretion.
Also, a recent retrospective case-control study over four years showed a statistically significant association between obesity and nephrotoxicity (odds ratio 3.2, 95% CI 1.19 to 8.67). Similarly, and not surprisingly, researchers observed a similar association between those receiving concomitant vancomycin (odds ratio 4.73, 95% CI, 1.57 to 14.25). Appropriate cautions are necessary when administering intravenous acyclovir to such higher-risk patients.
Acyclovir treatment can cause acute kidney injury because of acyclovir crystal formation in the renal tubules. Yalçinkaya R. et al. studied risk factors for acyclovir-induced acute kidney injury in children. The retrospective study had a total of 472 patients. Thirty-two had acute kidney injury—most patients presented with no symptoms. Risk factors were older age, obesity, current use of nephrotoxic drugs, higher baseline creatinine concentrations, higher dose, and longer duration of acyclovir use.
Enhancing Healthcare Team Outcomes
Administering intravenous acyclovir requires interprofessional effort and communication. It is not a benign drug, having potential side effects such as phlebitis, hypersensitivity, and AKI. Therefore, pharmacists, clinicians (MDs, DOs, NPs, and PAs), and nurses must work together to achieve adequate and non-toxic dosing. Clinicians will make the initial decision to use acyclovir. Dose adjustments for ideal body weight and baseline renal function are necessary. The pharmacist should coordinate this with nurses and clinicians for inpatients, verifying dosing and performing medication reconciliation, and altering other team members if there are any issues of concern. Also, patients must monitor signs/symptoms of hypersensitivity and phlebitis, specifically at the infusion site; this is where nurses will be best positioned to inform the rest of the healthcare team should there be any issues of concern. Interprofessional teamwork between each healthcare provider for a patient can help minimize and prevent the adverse effects of intravenous administration of acyclovir. [Level 5]